|
Filippi M, Rocca MA, Pagani E, De Stefano N, Jeffery D, Kappos L, Montalban X, Boyko AN, Comi G; ALLEGRO Study Group. Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage. J Neurol Neurosurg Psychiatry. 2014 Aug;85(8):851-8. doi: 10.1136/jnnp-2013-306132. Epub 2013 Sep 12. PubMed PMID: 24029546.
AÑO: 2014; IF: 8.263
|
24029546
|
Balaña M, Fabregas M, Meca-Lallana J, Mendibe M, Garcia E. Factors Associated with Caregiver's Burden in Relapsing-Remitting Multiple Sclerosis and Satisfaction with Current Therapies. MS-Feeling Study. Value Health. 2014 Nov;17(7):A402. doi: 10.1016/j.jval.2014.08.920. Epub 2014 Oct 26. PubMed PMID: 27200963.
AÑO: 2014; IF: 5.494
|
|
Meca-Lallana JE, Hernández-Clares R, Carreón-Guarnizo E. [Oral treatments in multiple sclerosis]. Med Clin (Barc). 2014 Dec;143 Suppl 3:23-9. doi: 10.1016/S0025-7753(15)30006-3. Review. Spanish. PubMed PMID: 25732946.
AÑO: 2014; IF: 1.417
|
|
Sanchez de la Rosa R, Garcia BL, Meca Lallana J. Cost Analysis of the Use of Glatiramer Acetate Compared to Interferon-Â in Patients with Relapsing-Remitting Multiple Sclerosis and Spasticity in Spain. Value Health. 2014 Nov;17(7):A394. doi: 10.1016/j.jval.2014.08.876. Epub 2014 Oct 26. PubMed PMID: 27200920.
AÑO: 2014; IF: 5.494
|
|
Fox RJ, Cree BA, De Seze J, Gold R, Hartung HP, Jeffery D, Kappos L, Kaufman M, Montalban X, Weinstock-Guttman B, Anderson B, Natarajan A, Ticho B, Duda P; RESTORE. MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study. Neurology. 2014 Apr 29;82(17):1491-8. doi: 10.1212/WNL.0000000000000355. Epub 2014 Mar 28. Erratum In: Neurology. 2015 Feb 24;84(8):862. multiple investigator names added. PubMed PMID: 24682966; PubMed Central PMCID: PMC4011468.
AÑO: 2014; IF: 9.9
|